Building trust again: 2-BBB and the long way back

 

Abstract

In the summer of 2014, Gaillard left to-BBB, the company he founded, because he did not agree with the new direction set out by the majority of directors and shareholders. The company had just received another round of financing, so there was more in our bank account than ever before. Less than six months later, the company filed for bankruptcy. This could have been the end of a promising startup, based on a new method to help drugs to pass the so-called blood brain barrier. But Gaillard decided to give his dream another chance. In March 2015, with the help of three investors, he bought back all relevant patents and data results from the administrator in the bankruptcy. He started rebuilding everything in order to resume product development, together with parties who understand and value our products. Lessons learned will be shared.

Dr. Pieter J. Gaillard

Co-founder and CEO, 2-BBB Medicines BV
Dr. Pieter J. Gaillard is a scientist and entrepreneur. He obtained a PhD degree in pharmacology from Leiden University. He founded and is now restarting the company to-BBB after the bankruptcy (2-BBB). Meanwhile he started a new therapeutic eye care company (Eyesiu). He is a member of the expert board at Skolkovo Foundation in Russia, advisory board at the Leiden BioSciencePark and member of the Supervisory Board of Leiden Marketing. With his team at to-BBB, he successfully raised six rounds of equity investments, ranging from seed to series C venture capital, and numerous non-dilutive credits and grants. In 2008, he licensed the G-Technology® from a Taiwanese research and technology institute (ITRI) as the company’s new and improved brain delivery platform. As to-BBB’s chief scientific officer, he effectively led the company through the discovery and preclinical phases of drug development, delivering the company’s lead product 2B3-101 in a clinical phase I/IIa brain cancer trial in 2011, and the company’s second product 2B3-201 for acute relapses in MS in a phase I trial in 2013. In the mean time, he and his team established numerous research collaborations with top tier pharmaceutical companies, foundations and academic groups to combine to-BBB's innovative approach with their potential drugs in development.

Jumpstart your career

Join BioBusiness Summer School to jumpstart your career in Life Sciences by gaining knowledge of business aspects such as product development, IPR, finance and business models. The next edition of the summer school will be organised from 25-29 June 2018 in Amsterdam, Leiden and Utrecht, the Netherlands. Register now!

Why participate

The BioBusiness Summer School is a programme tailored to bridge the gap. By immersing yourself in the business aspects of Life Sciences during this programme, you will learn the basic knowledge of BioBusiness, gain insight in the world of Life Sciences companies, meet leading business leaders and increase your international network.

Employers meet talent

Is your organisation interested in early-career talents in Life Sciences? BioBusiness Summer School can get you in touch with business oriented PhDs, postdocs or Master students. More info can be found here.